Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) was the target of a significant drop in short interest during the month of April. As of April 15th, there was short interest totalling 711,200 shares, a drop of 20.6% from the March 31st total of 895,200 shares. Based on an average trading volume of 3,910,000 shares, the short-interest ratio is presently 0.2 days.
CANF has been the topic of several recent research reports. Zacks Investment Research cut Can-Fite BioPharma from a “hold” rating to a “sell” rating in a report on Tuesday, March 30th. HC Wainwright restated a “buy” rating on shares of Can-Fite BioPharma in a report on Friday, February 26th.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Susquehanna International Group LLP acquired a new stake in shares of Can-Fite BioPharma during the fourth quarter worth about $27,000. Virtu Financial LLC raised its position in Can-Fite BioPharma by 445.7% in the 4th quarter. Virtu Financial LLC now owns 74,052 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 60,483 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in Can-Fite BioPharma by 812.7% in the 4th quarter. Renaissance Technologies LLC now owns 118,894 shares of the biotechnology company’s stock valued at $212,000 after buying an additional 105,867 shares during the last quarter. 0.57% of the stock is currently owned by institutional investors.
Can-Fite BioPharma (NYSEAMERICAN:CANF) last released its quarterly earnings results on Thursday, March 25th. The biotechnology company reported ($0.30) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.17). The business had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.50 million. Can-Fite BioPharma had a negative return on equity of 215.41% and a negative net margin of 1,648.57%. Equities analysts expect that Can-Fite BioPharma will post -1.43 EPS for the current year.
Can-Fite BioPharma Company Profile
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, COVID-19 and erectile dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.
Read More: Trade War
Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.